Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$101.50
+1.2%
$90.77
$73.04
$121.90
$6.56B0.83781,410 shs353,347 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$25.44
-1.2%
$23.26
$14.80
$40.47
$1.94B1.08826,675 shs653,529 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$12.66
-0.1%
$10.34
$8.02
$18.80
$6.29B1.495.07 million shs4.74 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$39.77
+2.5%
$37.55
$29.17
$62.40
$7.23B1.111.49 million shs1.40 million shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
0.00%-0.19%+17.90%+10.03%-1.18%
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%+0.04%+18.22%-8.65%-17.43%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%-2.10%+34.00%+14.95%-25.20%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.00%+0.58%+3.08%-3.80%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.7207 of 5 stars
3.41.00.00.02.90.80.6
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.3923 of 5 stars
4.51.00.00.03.30.80.0
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
3.1044 of 5 stars
3.22.00.00.33.13.30.0
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.3597 of 5 stars
4.51.00.04.73.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.83
Moderate Buy$126.5624.69% Upside
CG Oncology, Inc. stock logo
CGON
CG Oncology
3.00
Buy$58.22128.86% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.1719.77% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$67.0868.68% Upside

Current Analyst Ratings Breakdown

Latest CGON, RVMD, ELAN, and BPMC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/14/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$73.00 ➝ $72.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$67.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$87.00 ➝ $80.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
5/2/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$135.00 ➝ $135.00
5/2/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$41.00
5/1/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$128.00
(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$562.12M11.66N/AN/A$4.67 per share21.73
CG Oncology, Inc. stock logo
CGON
CG Oncology
$662K2,929.25N/AN/A($1.94) per share-13.11
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.42$2.62 per share4.84$12.63 per share1.00
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$742K9,983.66N/AN/A$11.09 per share3.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A156.15N/A-13.19%-77.49%-20.84%8/7/2025 (Estimated)
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$48.61M-$1.51N/AN/AN/A-10,642.98%-18.97%-15.36%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.7431.6614.232.504.60%6.78%3.03%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)

Latest CGON, RVMD, ELAN, and BPMC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/7/2025Q1 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.12-$1.13-$0.01-$1.13N/AN/A
5/1/2025Q1 2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
3/25/2025Q4 2024
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 million
2/26/2025Q4 2024
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A
2/25/2025Q4 2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.15$0.14-$0.01-$0.02$1.01 billion$1.02 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.15
2.85
2.80
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
35.32
35.32
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
14.24
14.24

Institutional Ownership

CompanyInstitutional Ownership
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
4.21%
CG Oncology, Inc. stock logo
CGON
CG Oncology
7.40%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
64064.58 million61.22 millionOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6176.23 millionN/AOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.65 million491.54 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.27 million154.76 millionOptionable

Recent News About These Companies

Revolution Medicines Inc.
Research Analysts Set Expectations for RVMD Q2 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$101.50 +1.16 (+1.16%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$105.00 +3.50 (+3.45%)
As of 05/23/2025 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$25.44 -0.32 (-1.24%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$25.62 +0.17 (+0.69%)
As of 05/23/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$12.66 -0.01 (-0.06%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$12.50 -0.17 (-1.33%)
As of 05/23/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$39.77 +0.97 (+2.50%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$39.98 +0.20 (+0.52%)
As of 05/23/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.